Search research articles
Contact Us
Filters
Showing results (301-310 of 314) with videos related to
Page
of 32
Sort By:
Journal of the National Cancer Institute
|
September 30, 2024
Automated patient selection and care coaches to increase advance care planning for patients with cancer
Michael F Gensheimer, Winifred Teuteberg, Manali I Patel, et al.
Therapeutic Advances in Medical Oncology
|
September 29, 2022
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Maria-Pilar Barretina-Ginesta, Bradley J Monk, Sileny Han, et al.
Journal of the American College of Cardiology
|
March 18, 2017
Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload
Marvin A Konstam, Michael Kiernan, Arthur Chandler, et al.
JAMA Cardiology
|
November 3, 2021
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
Douglas L Mann, Michael M Givertz, Justin M Vader, et al.
Circulation. Cardiovascular Quality and Outcomes
|
January 12, 2021
The Cardiovascular Quality Improvement and Care Innovation Consortium: Inception of a Multicenter Collaborative to Improve Cardiovascular Care
, Steven M Bradley, Srinath Adusumalli, et al.
Cureus
|
September 24, 2025
Surgical Outcomes of Open, Laparoscopic, and Robotic-Assisted Approaches for Stage I Endometrial Cancer: Insights From a Real-World Study by the Indian Gynecologic-Onco Study Group
Vandana Jain, Jaydip Bhaumik, Rama Joshi, et al.
Gynecologic Oncology
|
June 4, 2024
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Giorgio Valabrega, Bhavana Pothuri, Ana Oaknin, et al.
JACC. Heart Failure
|
July 10, 2020
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial
Douglas L Mann, Stephen J Greene, Michael M Givertz, et al.
Cancer
|
April 15, 2023
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Mansoor R Mirza, Antonio González-Martín, Whitney S Graybill, et al.
Gynecologic Oncology
|
February 7, 2024
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
Bhavana Pothuri, Sileny Han, Dana M Chase, et al.
Page
of 32
Search research articles
Search
Showing results (301-310 of 314) with videos related to
Sort By:
Page
of 32
Journal of the National Cancer Institute
|
September 30, 2024
Automated patient selection and care coaches to increase advance care planning for patients with cancer
Michael F Gensheimer, Winifred Teuteberg, Manali I Patel, et al.
Therapeutic Advances in Medical Oncology
|
September 29, 2022
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Maria-Pilar Barretina-Ginesta, Bradley J Monk, Sileny Han, et al.
Journal of the American College of Cardiology
|
March 18, 2017
Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload
Marvin A Konstam, Michael Kiernan, Arthur Chandler, et al.
JAMA Cardiology
|
November 3, 2021
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
Douglas L Mann, Michael M Givertz, Justin M Vader, et al.
Circulation. Cardiovascular Quality and Outcomes
|
January 12, 2021
The Cardiovascular Quality Improvement and Care Innovation Consortium: Inception of a Multicenter Collaborative to Improve Cardiovascular Care
, Steven M Bradley, Srinath Adusumalli, et al.
Cureus
|
September 24, 2025
Surgical Outcomes of Open, Laparoscopic, and Robotic-Assisted Approaches for Stage I Endometrial Cancer: Insights From a Real-World Study by the Indian Gynecologic-Onco Study Group
Vandana Jain, Jaydip Bhaumik, Rama Joshi, et al.
Gynecologic Oncology
|
June 4, 2024
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Giorgio Valabrega, Bhavana Pothuri, Ana Oaknin, et al.
JACC. Heart Failure
|
July 10, 2020
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial
Douglas L Mann, Stephen J Greene, Michael M Givertz, et al.
Cancer
|
April 15, 2023
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Mansoor R Mirza, Antonio González-Martín, Whitney S Graybill, et al.
Gynecologic Oncology
|
February 7, 2024
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
Bhavana Pothuri, Sileny Han, Dana M Chase, et al.
Page
of 32